Navigation Links
Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
Date:11/28/2012

HAYWARD, Calif., Nov. 28, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced additional data from its Phase 2b PEARL-SC study was presented in a poster at the 2012 Asian Lupus Summit. The poster entitled "The Subcutaneous BAFF Inhibitor, Blisibimod, Significantly Reduces Proteinuria in Subjects with Moderate-to-Severe Systemic Lupus Erythematosis," is being displayed at the conference today Wednesday, November 28, 2012.

In addition to the effects seen in the modified intent to treat population in the PEARL-SC study, which was presented at the recent 2012 ACR/ARHP conference, the poster highlights additional data related to the effect of blisibimod on renal disease in lupus. Both the pooled blisibimod treatment group and the 200 mg weekly blisibimod treatment group showed a statistically significant treatment reduction in proteinuria.  

"These data provide further rationale for broadening the CHABLIS-SC2 study population to include both patients with severe disease and patients suffering from lupus nephritis," said Colin Hislop, MD, Anthera's Senior Vice President and Chief Medical Officer. "These data will also guide our plans to pursue studies in IgA nephropathy and other renal diseases that involve B-cells."

The poster will be available on www.anthera.com.

About Blisibimod and PEARL-SC

BAFF has been associated with a wide range of B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, vasculitis, IgA nephropathy, immune thrombocytopenic purpura and others. Multiple clinical studies with other BAFF antagonists recently have reported on BAFF's potential positive role in treating lupus and rheumatoid arthritis. Anthera is advancing its development of blisibimod, a broad inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel fusion protein called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications. The PEARL-SC Phase 2 study was designed as a randomized, double-blind, placebo-controlled, dose-ranging superiority trial to evaluate the safety, tolerability and efficacy of blisibimod plus standard of care, versus placebo plus standard of care. A total of 547 patients with active SLE were randomized to receive one of three different doses of blisibimod or placebo (100 mg weekly, 200 mg weekly or 200 mg monthly) administered subcutaneously over a minimum 24-week treatment period, in addition to standard-of-care therapy. The study was conducted at multiple centers worldwide. 

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
2. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
3. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
4. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
5. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
6. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
7. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
8. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
9. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
10. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
11. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017 A ReportsnReports.com report says, over the ... as the global sales of Adcetris and Kadcyla have been witnessing ... drug conjugates market is driven by large number of ADC drugs ... window offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 Major Company Profiles, ...
(Date:3/24/2017)... INDIANAPOLIS , March 24, 2017  Eli ... today announced plans to invest $850 million in ... span facilities across its U.S. enterprise, including research ... The investments are being driven by demand for ... of potential medicines in development targeting cancer, pain, ...
(Date:3/24/2017)... The Board of Directors of Nordic Nanovector ASA (OSE: ... complete 2016 Annual Accounts with notes. The report is attached ... the section Investor Relations/Reports and presentations/Annual Reports. ... For further information, please ... Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com Media enquiries: ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Mediaplanet today announces ... on the current obstacles facing infection prevention and offer strategies for the health ... these infections. , The print component of “Fighting Infection” is distributed within ...
(Date:3/24/2017)... Farifax, VA (PRWEB) , ... March 24, 2017 , ... ... its 2017 Quest Awards . The annual awards, now in their 12th year, ... marketing peers selects the winners. , In 2016, the awards were retooled to recognize ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... The iaedp ... and other medical professionals caring for those suffering from the full spectrum of disordered ... 800, as eating disorders professionals from nearly all 50 states and several countries converged ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... over $100,000 for its innovative EcoQube Frame vertical micro-veggies garden on Kickstarter ... demand for the product – with nearly 2,000 consumers (and counting) already backing ...
(Date:3/24/2017)... ... March 24, 2017 , ... On June 9, 2017, ... Claims Litigation seminar in Chicago, Illinois. She will present on: , Filing ... litigated under ERISA involve claims for long-term disability benefits. This session will ...
Breaking Medicine News(10 mins):